By Dr Rodrigo Carlessi, Senior Research Fellow, Curtin University
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and carries a high disease burden.
Liver cancer (primarily HCC) is among the fastest-growing causes of cancer-related death in Australia. Approximately two-thirds of patients experience recurrence within five years of curative-intent therapy.
The standard follow-up for HCC survivors relies heavily on imaging and serum tumour markers, but each has significant limitations. Post-treatment surveillance typically involves periodic imaging (MRI or CT scans) and checking alpha-fetoprotein (AFP) levels....
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and carries a high disease burden.
Liver cancer (primarily HCC) is among the fastest-growing causes of cancer-related death in Australia. Approximately two-thirds of patients experience recurrence within five years of curative-intent therapy.
The standard follow-up for HCC survivors relies heavily on imaging and serum tumour markers, but each has significant limitations. Post-treatment surveillance typically involves periodic imaging (MRI or CT scans) and checking alpha-fetoprotein (AFP) levels....
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.